Standardized Grass Pollen, Bermuda 10000 [BAU]/mL Injection, Solution, 10 mL Vial — NDC 65044-0537-02 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 65044-0537-02: Standardized Grass Pollen, Bermuda 10000 [BAU]/mL Injection, Solution, 10 mL Vial

by Jubilant HollisterStier LLC

This is a package of 10 mL of Standardized Grass Pollen, Bermuda 10000 [BAU]/mL Injection, Solution from Jubilant HollisterStier LLC, no longer marketed (first marketed Jan 1998), no longer in the FDA NDC Directory.

🏷️ FDA NDC (as labeled) 65044-0537-2 billing pads the package segment with a zero
This package
Contains10 mL Pack sizes4 compare ↓
Brand Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Oct 22, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 65044-0537-2 alone.

Record
FDA NDC Directory package listing · Standardized allergenic
Code segments
65044 labeler · 0537 product · 2 package
Package marketed since
Jan 15, 1998
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 6504405372 7
FDA record last changed
Oct 22, 2026
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Jun 2017. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65044-0537-2
Product NDC 65044-0537
11-digit billing NDC 65044053702
Application # BLA103872
SPL Set ID 3b7a7f87-72f4-42cb-bc1b-55eefcf8d7dc
Established class (EPC) Standardized Pollen Allergenic Extract
Physiologic effect Cell-mediated Immunity; Increased Histamine Release; Increased IgG Production
Chemical class Allergens; Pollen
DEA schedule Non-controlled
Marketing category BLA
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Jun 2017)
Marketing start 1998-01-15
Route PERCUTANEOUS, SUBCUTANEOUS
Dosage form INJECTION, SOLUTION
Substance CYNODON DACTYLON POLLEN
Biologic (Purple Book) 351(a)
Why two NDCs? The FDA registers this code as 65044-0537-2 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 65044-0537-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 5 ml 30 ml 50 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
65044-0537-01 65044-0537-1 Main listing 5 mL in 1 VIAL 1998-01-15 — Discontinued by firm
65044-0537-02 You're viewing this 10 mL in 1 VIAL 1998-01-15 — Discontinued by firm
65044-0537-03 65044-0537-3 30 mL in 1 VIAL 1998-01-15 — Discontinued by firm
65044-0537-04 65044-0537-4 50 mL in 1 VIAL 1998-01-15 — Discontinued by firm

You're viewing one of 4 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 10 mL — 10 ml in 1 vial.
How does this package differ from NDC 65044-0537-01?
Both are Standardized Grass Pollen, Bermuda 10000 [BAU]/mL Injection, Solution — the drug itself is identical. This page's package is the 10 mL one, while NDC 65044-0537-01 is the 5 ml package.
What NDC number is used to bill for this package of Standardized Grass Pollen, Bermuda 10000 [BAU]/mL Injection, Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Bermuda Grass, Standardized 10000 [BAU]/mL 00268-0293-10 ALK-Abello, 10 ml — — FDA listed —
Bermuda Grass, Standardized 10000 [BAU]/mL 00268-3050-06 ALK-Abello, 5 ml — — FDA listed —
Standardized Bermuda Grass Pollen 10000 [BAU]/mL 22840-0200-02 Greer 10 ml — — FDA listed —
Standardized Bermuda Grass 10000 [BAU]/mL 49643-0342-05 Allermed 5 ml — — FDA listed —
Standardized Grass Pollen, Bermuda Grass 10000 [BAU]/mLthis 65044-0537-02 Jubilant 10 ml — — Discontinued —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
1924
First FDA approval
Mar 1924
📍
2026
Currently FDA-listed
102 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 8MDF5V39QO
    A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerJubilant HollisterStier LLC
FDA applicationBLA103872 (BLA)
Labeler code65044
First marketedJan 1998
Product typeStandardized Allergenic
Portfolio370 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning ~1 min read ▾

WARNING: ANAPHYLAXIS Standardized Grass Pollen Extracts can cause anaphylaxis, including anaphylactic shock and death 1 . ( 5.1 , 11 ) Do not administer to individuals with: severe, unstable or uncontrolled asthma; history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment; medical conditions that reduce the ability to survive anaphylaxis. ( 4 ) Observe individuals for at least 30 minutes following administration.

Emergency measures and healthcare providers trained in their use must be available in the event of a life‑threatening reaction. ( 5.1 ) Individuals with extreme sensitivity to these products, on an accelerated immunotherapy build-up, switching to another lot, receiving high doses of these products, or exposed to excessive amounts of grass pollen may be at increased risk of anaphylaxis. ( 5.1 ) These products may not be suitable for individuals who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

( 5.1 ) WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning . Standardized Grass Pollen Extracts can cause anaphylaxis, including anaphylactic shock and death. ( 5.1 ) Do not administer to individuals with severe, unstable or uncontrolled asthma, history of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment, or with medical conditions that reduce the ability to survive anaphylaxis.

( 4 ) Observe individuals for at least 30 minutes following administration. Emergency measures and healthcare providers trained in their use must be available in the event of a life-threatening reaction. ( 5.1 ) Individuals with extreme sensitivity to these products, on an accelerated immunotherapy build-up, switching to another lot, receiving high doses of these products, or exposed to excessive amounts of grass pollen may be at increased risk of anaphylaxis.

( 5.1 ) These products may not be suitable for individuals who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. ( 5.1 )

🎯 Indications and Usage 203 words ▾

1 INDICATIONS AND USAGE Standardized Grass Pollen Extracts [see Description ( 11 )] are indicated for: Skin testing for diagnosis of patients with a clinical history of allergy to one or more of the following grass pollen allergens: Bermuda, Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, or Timothy. 7 , 8 , 9 , 10 Immunotherapy for the reduction of grass pollen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for pollen-specific IgE antibodies for Bermuda grass pollen, Kentucky Blue (June) grass pollen, Meadow Fescue grass pollen, Orchard grass pollen, Perennial Rye grass pollen, Redtop grass pollen, Sweet Vernal grass pollen, or Timothy grass pollen.

Standardized Grass Pollen Extracts are indicated for ( 1 ): Skin test diagnosis of patients with a clinical history of allergy to one or more of the following grass pollen allergens: Bermuda,Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, or Timothy. Immunotherapy for the reduction of grass pollen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for pollen-specific IgE antibodies to one or more of the following grass pollens: Bermuda, Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, or Timothy.

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION For percutaneous, intradermal, or subcutaneous use only . Administration: Percutaneous for diagnostic testing Intradermal for diagnostic testing Subcutaneous for immunotherapy See full prescribing information for details on dosing and dilution preparation. ( 2 )

2.1Preparation for Administration Verify that the label on the vial states the intended specific standardized grass pollen extract to be administered. Standardized Grass Pollen Extracts should appear as clear to slightly opalescent solution with a light yellow to medium brown color. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Discard the solution if either of these conditions exist. Standardized Grass Pollen Extracts diluted with Albumin Saline with Phenol (0.4 %) (stabilized diluent) may be more potent than Standardized Grass Pollen Extracts diluted with diluents that do not contain albumin. When switching from non‑stabilized to stabilized diluent, consider less concentrated initial dilutions for both intradermal testing and immunotherapy.

Different formulations, preparations, or new lots of Standardized Grass Pollen Extracts are not substitutable. Adjust dosage appropriately when formulations, preparations, or lots of Standardized Grass Pollen Extracts are changed [see Immunotherapy ( 2.3 ) and Dosage Forms and Strengths ( 3 )] . Standardized Grass Pollen Extracts may be prepared for intradermal (diagnosis) or subcutaneous (immunotherapy) administration by diluting stock concentrates.

For diluent, use sterile albumin saline with phenol or sterile normal saline with phenol. Dilute stock concentrates by a minimum of 100-fold for intradermal testing. Dilutions of 1,000-fold or greater are appropriate starting points for patients with a clinical history of adverse reaction.

To prepare dilutions for intradermal testing and immunotherapy, start with a stock concentrate, and prepare a ten-fold (1:10) dilution by adding 0.5 mL of concentrate to 4.5 mL of sterile aqueous diluent. Prepare subsequent dilutions in a similar manner (see Table 1). Table 1: 10-fold Dilution Series for Standardized Grass Pollen Extracts Labeled 10,000 BAU/mL* and 100,000 BAU/mL* Dilution** Extract Volume of Diluent Dilution Strength BAU/mL (Bermuda Grass) Dilution Strength BAU/mL (All other Individual Grasses, except Bermuda Grass) 0 Stock Concentrate 0 mL 10,000 100,000 1 0.5 mL Concentrate 4.5 mL 1,000 10,000 2 0.5 mL Dilution 1 4.5 mL 100 1,000 3 0.5 mL Dilution 2 4.5 mL 10 100 4 0.5 mL Dilution 3 4.5 mL 1 10 5 0.5 mL Dilution 4 4.5 mL 0.1 1 6 0.5 mL Dilution 5 4.5 mL 0.01 0.1 7 0.5 mL Dilution 6 4.5 mL 0.001 0.01 * BAU/mL = Bioequivalent Allergy Units/mL ** Store extract dilutions at 2 to 8 °C (36 to 46 °F).

2.2Diagnostic Testing For percutaneous and intradermal use only. Use individual standardized grass pollen extracts to identify patients who exhibit an allergic response to specific species of grass pollen. False positive reactions may occur.

A positive skin test reaction must be interpreted in the context of the individual’s clinical history and known exposure to the allergen. Administer percutaneous tests prior to administration of intradermal tests. A positive reaction with grass pollen mixtures during diagnostic testing does not permit identification of the specific grass pollen allergen that elicited the reaction.

Additionally, a negative reaction fails to indicate whether an individual component allergen would have elicited a positive reaction at full strength. Percutaneous Skin Testing Dose Unless an individual is suspected to be at greater risk for anaphylaxis, the initial starting dose is 1 drop (approximately 0.05 mL) of concentrated standardized grass pollen extract. For individuals suspected to be at greater risk for anaphylaxis such as those with a history of allergen-induced anaphylaxis, initiate percutaneous testing with 1 drop of a d… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths ~1 min read ▾

3 DOSAGE FORMS AND STRENGTHS Injection. Standardized Grass Pollen Extracts are labeled in Bioequivalent Allergy Units per milliliter (BAU/mL). [see Description ( 11 )] Refer to the vial label for the product concentration [see How Supplied/Storage and Handling ( 16.1 )]. For percutaneous testing, standardized Bermuda grass pollen extract stock concentrate containing 10,000 BAU/mL of grass pollen is supplied in 10 mL multiple-dose vials.

All other standardized grass pollen extract stock concentrates containing 100,000 BAU/mL of grass pollen are supplied in 5 mL dropper vials [see Description ( 11 ) ]. For intradermal testing, standardized Bermuda grass pollen extract stock concentrate is available in 10,000 BAU/mL of grass pollen. All other standardized grass pollen extract stock concentrates are available in 100,000 BAU/mL.

All standardized grass pollen extract stock concentrates are supplied in 10 mL and 50 mL multiple-dose vials [see Description ( 11 ) ]. For immunotherapy, standardized Bermuda grass pollen extract stock concentrate is available in 10,000 BAU/mL. All other standardized grass pollen extract stock concentrates are available in 100,000 BAU/mL.

All standardized grass pollen extract stock concentrates are supplied in 10 mL and 50 mL multiple-dose vials [see Description ( 11 ) ]. Injection. Standardized Grass Pollen Extracts are labeled in Bioequivalent Allergy Units per milliliter (BAU/mL).

( 3 , 11 ) Refer to the vial label for the product concentration. ( 16 ) Standardized Bermuda grass pollen extract: 10,000 BAU/mL stock concentrate in a multiple-dose vial. ( 3 ) All other Standardized Grass Pollen Extracts (except Bermuda grass pollen): 100,000 BAU/mL stock concentrate in a multiple-dose dropper vial and in a multiple-dose vial.

( 3 )

⛔ Contraindications 79 words ▾

4 CONTRAINDICATIONS Standardized Grass Pollen Extracts are contraindicated in individuals with: Severe, unstable or uncontrolled asthma. History of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment. Medical conditions that reduce the ability to survive anaphylaxis.

Severe, unstable or uncontrolled asthma. ( 4 ) History of any severe systemic reaction to the allergen extract when administered for diagnosis or treatment.( 4 ) Medical conditions that reduce the ability to survive anaphylaxis. ( 4 )

⚠️ Warnings and Cautions ~1 min read ▾

5 WARNINGS AND PRECAUTIONS The risk of anaphylaxis may be increased in the following situations ( 5.1 ): Extreme sensitivity to Standardized Grass Pollen Extracts. Receipt of an accelerated build-up schedule. Change from one lot of a particular standardized grass pollen extract to another lot of the same standardized grass pollen extract. Receipt of high doses of the Standardized Grass Pollen Extracts. Exposure to excessive amounts of grass pollen.

5.1Anaphylaxis Anaphylaxis, which may lead to death, can occur in individuals following the administration of Standardized Grass Pollen Extracts, particularly in the following situations [see Adverse Reactions ( 6 )]: 18 , 19 , 20 , 21 Extreme sensitivity to the Standardized Grass Pollen Extracts. Receipt of an accelerated build-up schedule. Change from one lot of a particular standardized grass pollen extract to another lot of the same standardized grass pollen extract.

Receipt of high doses of the Standardized Grass Pollen Extracts. Exposure to excessive amounts of grass pollen. Standardized Grass Pollen Extracts may not be suitable for individuals who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta‑blockers.

Medications to treat systemic reactions, as well as emergency equipment should be available for immediate use. Administer Standardized Grass Pollen Extracts in a healthcare setting under the supervision of a healthcare provider prepared to manage anaphylaxis. Individuals should remain in the provider’s office for a minimum of 30 minutes after receiving an injection of Standardized Grass Pollen Extracts, so that any adverse reaction can be observed and appropriately managed.

🤒 Adverse Reactions ~1 min read ▾

6 ADVERSE REACTIONS Common adverse reactions reported for allergenic extracts are: Local adverse reactions occurred in 26 to 82 % of all patients who received subcutaneous immunotherapy, at the injection site (e.g., erythema, swelling, pruritus, tenderness and pain). 23 Systemic adverse reactions occurred in ≤ 7 % of patients who received subcutaneous immunotherapy (e.g., generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, hypotension, and shock). 24 Systemic reactions may be fatal.

1 , 12 , 23 Published studies of allergenic extracts report systemic reactions occurring in fewer than 1% in patients receiving conventional immunotherapy and greater than 36% in patients receiving rush immunotherapy. 1 , 12 , 26 , 27 Most systemic reactions occurred within 30 minutes of injection. However, systemic reactions have been reported to occur up to 2 hours after the final injection with rush schedules.

Some reactions have occurred up to 6 hours after skin tests or immunotherapy. 23 , 24 , 28 Commonly reported adverse reactions for allergenic extracts are: Local adverse reactions occurred in 26 to 82 % of all patients who received subcutaneous immunotherapy (e.g., erythema, swelling, pruritus, tenderness and pain at the injection site). ( 6 ) Systemic adverse reactions occurred in ≤ 7 % of patients who received subcutaneous immunotherapy (e.g., generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, hypotension, and shock).

Systemic adverse reactions may be fatal. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Jubilant HollisterStier at 1-800-495-7437 or [email protected]; or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions 174 words ▾

7 DRUG INTERACTIONS Certain medications may decrease skin test wheal and erythema responses including antihistamine ( 7.1 ), topical corticosteroids and topical anesthetics ( 7.2 ), tricyclic Antidepressants ( 7.3 ).

7.1Antihistamines Do not perform skin testing with Standardized Grass Pollen Extracts within 3 to 10 days of first-generation H1‑histamine receptor blockers (e.g., clemastine, diphenhydramine) and second-generation antihistamines (e.g., loratadine, fexofenadine) being used. These products suppress histamine skin test reactions and could mask a positive response. 13 , 22 , 23

7.2Topical Corticosteroids and Topical Anesthetics Topical corticosteroids may suppress skin reactivity; therefore, discontinue use at the skin test site for at least 2 to 3 weeks before skin testing. 13 , 14 Avoid use of topical local anesthetics at skin test sites because they can suppress flare responses. 16 , 22 , 23

7.3Tricyclic Antidepressants Tricyclic antidepressants, such as doxepin, can have potent antihistamine effects and may alter skin test results. Allow 7 to 14 days after discontinuation of tricyclic medication prior to skin testing. 15 , 22 , 23

👥 Use in Specific Populations ~1 min read ▾

8 USES IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20 %, respectively. There are no human or animal data to establish the presence or absence of Standardized Grass Pollen Extracts associated risks during pregnancy. 17

8.2Lactation Risk Summary It is not known whether Standardized Grass Pollen Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Standardized Grass Pollen Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.

8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patient’s ability to comply and cooperate with receipt of the product and the potential for difficulty in communicating with the child regarding systemic reactions. 11 , 23 The volume of a dose for immunotherapy may need to be divided for pediatric patients [see Immunotherapy ( 2.3 )].

8.5Geriatric Use Data are not available to determine if patients 65 years of age and older respond differently to allergen immunotherapy than younger patients. 3

🤰 Pregnancy 70 words ▾

8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20 %, respectively. There are no human or animal data to establish the presence or absence of Standardized Grass Pollen Extracts associated risks during pregnancy. 17

🧒 Pediatric Use 69 words ▾

8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patient’s ability to comply and cooperate with receipt of the product and the potential for difficulty in communicating with the child regarding systemic reactions. 11 , 23 The volume of a dose for immunotherapy may need to be divided for pediatric patients [see Immunotherapy ( 2.3 )].

🧓 Geriatric Use 26 words ▾

8.5Geriatric Use Data are not available to determine if patients 65 years of age and older respond differently to allergen immunotherapy than younger patients. 3

🧬 Clinical Pharmacology 19 words ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The mechanisms of action of allergen immunotherapy have not been fully established.

🧬 Mechanism of Action 16 words ▾

12.1Mechanism of Action The mechanisms of action of allergen immunotherapy have not been fully established.

📦 How Supplied / Storage and Handling ~1 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied Standardized Grass Pollen Extracts are supplied as 50 % glycerin stock concentrates labeled in Bioequivalent Allergenic Units per Milliliter (BAU/mL) and provided in 10 mL and 50 mL multiple-dose vials for percutaneous and intradermal skin testing and subcutaneous immunotherapy. These extracts may also be supplied in 5 mL multiple-dose dropper vials for percutaneous testing only. These products are supplied as listed in Table 2.

Table 2: Available Standardized Grass Pollen Extracts Extracts Strength NDC Vial Size Standardized Grass Pollen, Bermuda Grass (Cynodon dactylon) 10,000 BAU/mL 65044-0537-2 10 mL 65044-0537-4 50 mL Standardized Grass Pollen, Kentucky Blue (June) (Poa pratensis) 100,000 BAU/mL 65044-0546-1 5 mL 65044-0546-2 10 mL 65044-0546-4 50 mL Standardized Grass Pollen, Fescue, Meadow ( Festuca elatior ) 100,000 BAU/mL 65044-0612-1 5 mL 65044-0612-2 10 mL 65044-0612-4 50 mL Standardized Grass Pollen, Orchard Grass (Dactylis glomerata) 100,000 BAU/mL 65044-0719-1 5 mL 65044-0719-2 10 mL 65044-0719-4 50 mL Standardized Grass Pollen, Redtop (Agrostis alba) 100,000 BAU/mL 65044-0778-1 5 mL 65044-0778-2 10 mL 65044-0778-4 50 mL Standardized Grass Pollen, Perennial Ryegrass (Lolium perenne) 100,000 BAU/mL 65044-0788-1 5 mL 65044-0788-2 10 mL 65044-0788-4 50 mL Standardized Grass Pollen, Sweet Vernal Grass (Anthoxanthum odoratum) 100,000 BAU/mL 65044-0826-1 5 mL 65044-0826-2 10 mL 65044-0826-4 50 mL Standardized Grass Pollen, Timothy (Phleum pratense) 100,000 BAU/mL 65044-0832-1 5 mL 65044-0832-2 10 mL 65044-0832-4 50 mL Standardized Grass Mix #4 (25% each of Poa pratensis , Dactylis glomerata , Agrostis alba , Phleum pratense ) 100,000 BAU/mL 65044-0842-1 5 mL 65044-0842-2 10 mL 65044-0842-4 50 mL

16.2Storage and Handling Store extracts at 2 to 8 °C (36 to 46 °F). Dilutions with under 50% glycerin are less stable. If potency loss is suspected, verify the potency by skin testing with equal units of a freshly prepared dilution on individuals with known pollen allergies.

📋 Description ~1 min read ▾

11 DESCRIPTION This prescribing information covers eight Standardized Grass Pollen Extracts. The term 'Standardized Grass Pollen Extracts' as used throughout labeling specifically refers to all eight products listed in the Product Title in Highlights of Prescribing Information. Standardized Grass Pollen Extracts include Standardized Bermuda Grass Pollen (Cynodon dactylon) at 10,000 BAU/mL, 0.5 % sodium chloride, 0.275 % sodium bicarbonate and 50 % glycerin by volume as a preservative and Standardized Kentucky Blue (June) Grass Pollen (Poa pratensis) , Standardized Meadow Fescue Grass Pollen (Festuca elatior) , Standardized Orchard Grass Pollen (Dactylis glomerata) , Standardized Perennial Rye Grass Pollen (Lolium perenne) , Standardized Redtop Grass Pollen (Agrostis alba) , Standardized Sweet Vernal Grass Pollen (Anthoxanthum odoratum) , and Standardized Timothy Grass Pollen (Phleum pratense) at 100,000 BAU/mL, 0.5 % sodium chloride, 0.275 % sodium bicarbonate, and 50 % glycerin by volume as a preservative.

Inactive ingredients include 0.25% sodium chloride for isotonicity and 0.25% sodium bicarbonate as a buffer. Standardized Grass Pollen Extracts are administered percutaneously, intradermally and subcutaneously. Standardized Grass Pollen Extracts are clear light yellow to brownish solutions that are free of particulate matter.

Standardized Grass Pollen Extracts are labeled in BAU/milliliter. Bioequivalent Allergy Units are assigned based on comparison by enzyme-linked immunosorbent assay (ELISA) to references from the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER).

CBER references are assigned unitage based on quantitative skin testing. 2 , 4 , 5 , 6 CBER references which can be diluted 1:5,000,000 to intradermally elicit a 50 millimeter sum of erythema diameter response in highly puncture reactive subjects are assigned 100,000 BAU/milliliter; whereas references diluted 1:500,000 which elicit the same 50 millimeter sum of erythema diameter response are assigned 10,000 BAU/milliliter.

💬 Information for Patients 114 words ▾

17 PATIENT COUNSELING INFORMATION Instruct patients to remain in the office under observation for a minimum of 30 minutes after an injection or longer, if deemed necessary for the individual. Inform patients that reactions may occur more than 30 minutes after skin testing or an injection. Instruct patients to recognize the following symptoms as systemic adverse reactions and seek emergency medical care right away if any of these occur: Unusual swelling and/or tenderness at the injection site Hives or itching of the skin Swelling of face and/or mouth Sneezing, coughing, or wheezing Shortness of breath Nausea Dizziness or faintness Manufacturer: Jubilant HollisterStier LLC Spokane, WA 99207 U.S.A.

U.S. Lic. No.

1272 385407-H09 Company Logo

🍼 Nursing Mothers 76 words ▾

8.2Lactation Risk Summary It is not known whether Standardized Grass Pollen Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Standardized Grass Pollen Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.

🔬 Clinical Studies 46 words ▾

14 CLINICAL STUDIES Specific immunotherapy with allergenic extracts is helpful in reducing symptoms associated with exposure to the offending allergens. A summary of effectiveness by the Panel on Review of Allergenic Extracts, an advisory committee to the U.S. Food and Drug Administration, has been published. 25

🧪 Nonclinical Toxicology 24 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies in animals have been performed to evaluate carcinogenicity, mutagenicity or impairment of fertility.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 21 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No studies in animals have been performed to evaluate carcinogenicity, mutagenicity or impairment of fertility.

📚 References ~3 min read ▾

15 REFERENCES Lockey, Richard F., Linda M. Benedict, Paul C. Turkeltaub, Samuel C.

Bukantz. Fatalities from immunotherapy (IT) and skin testing (ST). J.

Allergy Clin. Immunol., 79 (4): 660-677, 1987. U.S.

Food & Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER). ELISA competition assay (Enzyme-linked Immunosorbent Assay). Methods of Allergenic Products Testing Laboratory.

October 1993. CBER Docket No. 94N.0012.

Peebles, Ray Stokes, Jr., B. Bochner, Howard J. Zeitz, ed.

Anaphylaxis in the elderly. Immunology and Allergy Clinics of North America. 13 (3): 627-646, August 1993.

Turkeltaub, PC, S. Rastogi. Quantitative intradermal test procedure for evaluation of subject sensitivity to standardized allergenic extracts and for assignment of bioequivalent allergy units to reference preparations using the ID50EAL method, Allergenic Products Testing Laboratory, Center for Biologics Evaluation and Research (CBER), FDA.

Revised November 1994. Turkeltaub PC, Rastogi SC, Baer H, et al. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results.

J Allergy Clin Immunol . 1982; 70:343-352. Turkeltaub PC.

Assignment of bioequivalent allergy units based on biological standardization methods. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M . 1988;(82):19-40.

Sheldon, J. M., R. G.

Lovell, K. P. Matthews.

A Manual of Clinical Allergy. Second Edition. W.B.

Saunders, Philadelphia, 1967, pp. 107-112. Sherman, W.

B. Hypersensitivity mechanism and management. W.

B. Sanders, Philadelphia, 1968, pp. 169-172.

Swineford, O. Asthma and Hay Fever. Charles C.

Thomas, Springfield, IL, 1971, pp. 148-155. Patterson, Roy, et al.

Allergy Principles and Practice, 2nd ed. E. Middleton, Jr., C.E.

Reed, E.F. Ellis, Ed., C.V. Mosby Co., 1983, St.

Louis, MO, 1983, Chapter 52. Levy, D.A., L.M. Lichtenstein, E.O.

Goldstein, and K. Ishizaka. Immunologic and cellular changes accompanying the therapy of pollen allergy.

J. Clinical Investigation, 50:360, 1971. Turkeltaub, Paul C., MD, and Peter J.

Gergen, MD. The risk of adverse reactions from percutaneous prick-puncture allergen skin testing, venipuncture, and body measurements: data from the Second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J.

Allergy Clin. Immunol. 84(6): 886-890, Dec.

1989. Pipkorn, Ulf. Pharmacological influence of anti-allergic medication on In Vivo allergen testing.

Allergy. 43: 81-86, 1988. Andersson, M. and U.

Pipkorn. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids. J.

Allergy Clin. Immunol. 79 (2): 345-349, February 1987.

Rao, Kamineni S., et al. Duration of suppressive effect of tricyclic anti-depressants on histamine induced wheal and flare reactions on human skin. J.

Allergy Clin. Immunol. 82: 752-757, November 1988.

Pipkorn, Ulf, and M. Andersson. Topical dermal anesthesia inhibits the flare but not the wheal response to allergen and histamine in the skin prick test.

Clinical Allergy. 17: 307-311, 1987. Metzger, W.J., E.

Turner and R. Patterson. The safety of immunotherapy during pregnancy.

J. Allergy Clin. Immunol.

61 (4): 268-272, 1978. Reid, M.J., R.F. Lockey, P.C.

Turkletaub, T.A.E. Platts-Mills. Survey of fatalities from skin testing and immunotherapy.

J. Allergy Clin. Immunol.

92 (1): 6-15, July 1993. Reid, M.J., G. Gurka.

Deaths associated with skin testing and immunotherapy. J. Allergy Clin.

Immunol. 97(1) Part 3:231, Abstract 195, January 1996. Thompson, R.A. et al, report of a WHO/IUIS working group.

The current status of allergen immunotherapy (hyposensitization). Allergy. 44: 369-379, 1989.

Malling, H.-J., B. Weeke, et al, The European Academy of Allergology and Clinical Immunology. Position Papers.

Allergy. 48 (Supplement 14): 9-82, 1993. Bernstein IL, Li JT, Bernstein Dl, et al.

Allergy diagnostic testing: an updated… [Excerpted — this section continues on DailyMed.]

📄 Recent Major Changes 3 words ▾

RECENT MAJOR CHANGES

📄 Package Label / Principal Display Panel ~3 min read ▾

PRINCIPAL DISPLAY PANEL 5mL Standardized Grass Pollen, Carton 0545TS - 5mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545TS - 5mL Standardized Grass Pollen, Kentucky Bluegrass, June - Container Label 0611TS - 5mL Standardized Grass Pollen, Meadow Fescue - Carton Label 0611TS - 5mL Standardized Grass Pollen, Meadow Fescue - Container Label 0718TS - 5mL Standardized Grass Pollen, Orchard Grass - Carton Label 0718TS - 5mL Standardized Grass Pollen, Orchard Grass - Container Label 0777TS - 5mL Standardized Grass Pollen, Redtop - Carton Label 0777TS - 5mL Standardized Grass Pollen, Redtop - Container Label 0787TS - 5mL Standardized Grass Pollen, Perennial Ryegrass - Carton Label 0787TS - 5mL Standardized Grass Pollen, Perennial Ryegrass - Container Label 0825TS - 5mL Standardized Grass Pollen, Sweet Vernal Grass - Carton Label 0825TS - 5mL Standardized Grass Pollen, Sweet Vernal Grass - Container Label 0831TS - 5mL Standardized Grass Pollen, Timothy - Carton Label 0831TS - 5mL Standardized Grass Pollen, Timothy - Container Label 0841TS - 5mL Standardized Grass Pollen, Grass Mix 4 - Carton Label 0841TS - 5mL Standardized Grass Pollen, Grass Mix 4 - Container Label 10mL Standardized Grass Pollen, Carton 0537TJ - 10mL Standardized Grass Pollen, Bermuda Grass - Carton Label 0537TJ - 10mL Standardized Grass Pollen, Bermuda Grass - Container Label 0545TW - 10mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545TW - 10mL Standardized Grass Pollen, Kentucky Bluegrass, June - Container Label 0611TW - 10mL Standardized Grass Pollen, Meadow Fescue - Carton Label 0611TW - 10mL Standardized Grass Pollen, Meadow Fescue - Container Label 0718TW - 10mL Standardized Grass Pollen, Orchard Grass - Carton Label 0718TW - 10mL Standardized Grass Pollen, Orchard Grass - Container Label 0777TW - 10mL Standardized Grass Pollen, Redtop - Carton Label 0777TW - 10mL Standardized Grass Pollen, Redtop - Container Label 0787TW - 10mL Standardized Grass Pollen, Perennial Ryegrass - Carton Label 0787TW - 10mL Standardized Grass Pollen, Perennial Ryegrass - Container Label 0825TW - 10mL Standardized Grass Pollen, Sweet Vernal Grass - Carton Label 0825TW - 10mL Standardized Grass Pollen, Sweet Vernal Grass - Container Label 0831TW - 10mL Standardized Grass Pollen, Timothy - Carton Label 0831TW - 10mL Standardized Grass Pollen, Timothy - Container Label 0841TW - 10mL Standardized Grass Pollen, Grass Mix 4 - Carton Label 0841TW - 10mL Standardized Grass Pollen, Grass Mix 4 - Container Label 50mL Standardized Grass Pollen, Carton 0537TL - 50mL Standardized Grass Pollen, Bermuda Grass - Carton Label 0537TL - 50mL Standardized Grass Pollen, Bermuda Grass - Container Label 0545TY - 50mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545TY - 50mL Standardized Grass Pollen, Kentucky Bluegrass, June - Container Label 0611TY - 50mL Standardized Grass Pollen, Meadow Fescue - Carton Label 0611TY - 50mL Standardized Grass Pollen, Meadow Fescue - Container Label 0718TY - 50mL Standardized Grass Pollen, Orchard Grass - Carton Label 0718TY - 50mL Standardized Grass Pollen, Orchard Grass - Container Label 0777TY - 50mL Standardized Grass Pollen, Redtop - Carton Label 0777TY - 50mL Standardized Grass Pollen, Redtop - Container Label 0787TY - 50mL Standardized Grass Pollen, Perennial Ryegrass - Carton Label 0787TY - 50mL Standardized Grass Pollen, Perennial Ryegrass - Container Label 0825TY - 50mL Standardized Grass Pollen, Sweet Vernal Grass - Carton Label 0825TY - 50mL Standardized Grass Pollen, Sweet Vernal Grass - Container Label 0831TY - 50mL Standardized Grass Pollen, Timothy - Carton Label 0831TY - 50mL Standardized Grass Pollen, Timothy - Container Label 0841TY - 50mL Standardized Grass Pollen, Grass Mix 4 - Carton Label 0841TY - 50mL Standardized Grass Pollen, Grass Mix 4 - Container Label 5mL Standardized Grass Pollen, Carton 0545TS - 5mL Standardized Grass Pollen, Kentucky Bluegrass, June - Carton Label 0545… [Excerpted — this section continues on DailyMed.]

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 5 ml (65044-0537-01), 30 ml (65044-0537-03), 50 ml (65044-0537-04). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Jubilant HollisterStier LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.